Articles

Ulcerative Colitis Therapeutics Pipeline Analysis, 2017

by Deepak Kumar Sr. SEO Executive

Ulcerative colitis is a chronic inflammatory disease, which basically affects colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. 

The leading cause of Ulcerative colitis therapeutics is the imbalance in regulation of gastrointestinal immune system. According to the International Society for Pharmacoeconomic and Outcomes Research journal named as value in health, the prevalence of ulcerative colitis has increased from 243 to 263 per 100,000 people each year in the U.S. Ulcerative colitis usually affects the upper layer of all parts of intestine mostly in colon and rectum. 

Read report summary here : http://bit.ly/2peUSeS

The main causes of the disease are genetic susceptibility and environmental factors such as, microbiological, smoking, immunological and psychological factors.

The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab which were approved for treatment of moderate to severe form of ulcerative colitis in patients who has failed to respond to the other conventional therapies such as, corticosteroids, mesalazine and 5-Aminosalicylic acid. The 5-Aminosalicylic acid is currently used as the first line of therapy for ulcerative colitis and the number of reported cases of relapse of disease or refractory cases are very low.

Request report sample here : http://bit.ly/2pm7MYL

Key Players

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.



About Deepak Kumar Advanced   Sr. SEO Executive

123 connections, 0 recommendations, 345 honor points.
Joined APSense since, May 30th, 2017, From New York, United States.

Created on Mar 16th 2018 05:49. Viewed 480 times.

Comments

No comment, be the first to comment.
Please sign in before you comment.